• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract 138: Impact of Depressive Disorder on Access to Care and Quality of Care in Veterans With Cardiovascular Disease Session Title: Poster Session II
Conclusions: Depressive disorder was associated with higher rates of financial barriers to care and prescription drugs, and patient-reported delays in medical care in U.S. veterans with CVD. Further research appears warranted to evaluate the impact of mental health disease upon cardiovascular care in veterans with CVD.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Srivastava, P., Lacey, M., Butler, J., Shroyer, A. L., Parikh, P. B. Tags: Session Title: Poster Session II Source Type: research

Abstract 139: Comparison of Access to Care and Quality of Care in Veterans versus Non-veterans With Cardiovascular Disease Session Title: Poster Session II
Conclusion: Veterans with CVD receive improved access to care and quality of care compared to their non-veteran counterparts.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Srivastava, P., Lacey, M., Butler, J., Shroyer, A. L., Parikh, P. B. Tags: Session Title: Poster Session II Source Type: research

Abstract 328: Cardiovascular Disease Associated with Ability to Achieve Renal Transplant and Post-Transplant Adverse Events Session Title: Poster Session III
Conclusions: CVD is common in patients listed for renal transplant. CAD is independently associated with lower odds of receiving a transplant. CAD and rEF are independently associated with increased hazard of post-transplant death or graft failure. Future efforts should focus measures to optimize outcomes in patients with CVD awaiting transplant.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ismail, S. J., Patel, M., Gindi, R., Salah, A., Tang, I., Benedetti, E., Ardati, A. Tags: Session Title: Poster Session III Source Type: research

Abstract 372: Health Outcomes Associated With Triple Antiplatelet Therapy for the Secondary Prevention of Atherothrombotic Events Session Title: Poster Session III
Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of atherothrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD), based on the findings of the TRA 2°P-TIMI 50 trial for patients without a history of stroke or transient ischemic attack. This analysis evaluated the health outcomes of triple antiplatelet therapy with vorapaxar when added to a standard care regimen of clopidogrel plus aspirin (ASA) in comparison with standard care alone, for patients without a history of transient ischemic attack or ...
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ozer-Stillman, I., Whalen, J. D., Bash, L. D., Oguz, M., Du, M., Singhal, P. K., Davies, G. M. Tags: Session Title: Poster Session III Source Type: research

Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women: Results From the Women's Health Initiative Original Articles
Conclusions— Regular use of selective cox-2 inhibitors and nonselective NSAIDs with cox-2>cox-1 inhibition showed a modestly increased hazard for cardiovascular events. Nonselective agents with cox-1>cox-2 inhibition were not associated with increased cardiovascular risk. Clinical Trial Registration— URL: www.clinicaltrials.gov. Unique identifier: NCT00000611.
Source: Circulation: Cardiovascular Quality and Outcomes - July 15, 2014 Category: Cardiology Authors: Bavry, A. A., Thomas, F., Allison, M., Johnson, K. C., Howard, B. V., Hlatky, M., Manson, J. E., Limacher, M. C. Tags: Risk Factors Original Articles Source Type: research

Abstract 385: The Impact of Aspirin Primary Prevention Treatment Guidelines: Temporal Trends in Aspirin Use for Primary vs Secondary Prevention, 2005-2013 Session Title: Poster Session III
Conclusion: Secondary prevention ASA use in primary care settings remains high, but ASA use for primary prevention of cardiovascular events is low. Despite creation of national guidelines, aspirin use in the PP population is half the rate of ASA use for secondary prevention. Additional methods to safely and effectively disseminate this primary prevention aspirin use recommendation, targeting both the public and health care providers, are warranted.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Van't Hof, J. R., Oldenburg, N., Duval, S., Dronca, S., Olson, A., Peterson, K., Leupker, R. V., Miller, K., Hirsch, A. T. Tags: Session Title: Poster Session III Source Type: research

Abstract 150: Resource Utilization Patterns and Outcomes Among Acute Coronary Syndrome Patients: Findings From a Multi-Payer Analysis Poster Session II
Conclusion: These findings suggest that many patients with ACS do not receive appropriate recommended antithrombotic prophylaxis, and opportunities exist to improve therapy. Increased use of software tools such as AQuA may support enhanced education efforts aimed at improving adherence to guidelines and quality of care.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Lang, K., Bozkaya, D., Patel, A. A., Macomson, B., Crivera, C., Owens, G., Mody, S. Tags: Poster Session II Source Type: research